Amgen Launches Direct-to-Patient Program for Repatha in the US

Amgen, a leading biotechnology company, is revolutionizing access to its cholesterol-lowering medication, Repatha, by launching the AmgenNow initiative in the US. This direct-to-patient program is designed to simplify and expedite the process of obtaining Repatha, enhancing patient accessibility and potentially impacting the broader pharmaceutical landscape by setting a new standard for drug availability and convenience.

Amgen’s decision to roll out AmgenNow comes in response to growing demands for more accessible and patient-centric healthcare solutions. By providing a direct channel for patients to access Repatha, Amgen is addressing both logistical and financial barriers often associated with prescription medications. Repatha, known for its efficacy in reducing cardiovascular risks, is now positioned to reach a larger segment of patients who can benefit from its life-saving potential. This move aligns with industry trends favoring patient empowerment and streamlining healthcare delivery, potentially influencing competitors to adopt similar strategies.